Shares of Insmed Inc. (NASDAQ:INSM) have earned an average rating of “Buy” from the seven analysts that are covering the company. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $20.75.
A number of brokerages have weighed in on INSM. Zacks Investment Research upgraded Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, September 21st. Piper Jaffray Cos. set a $24.00 target price on Insmed and gave the stock a “buy” rating in a research note on Sunday, August 21st.
Insmed (NASDAQ:INSM) traded down 0.73% during trading on Monday, hitting $13.64. The company had a trading volume of 108,896 shares. The company’s 50 day moving average price is $14.16 and its 200-day moving average price is $12.27. The stock’s market capitalization is $844.00 million. Insmed has a 1-year low of $9.02 and a 1-year high of $21.14.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by $0.03. On average, analysts expect that Insmed will post ($2.30) EPS for the current year.
Several institutional investors have recently made changes to their positions in INSM. Pacad Investment Ltd. purchased a new position in shares of Insmed during the second quarter valued at approximately $124,000. TFS Capital LLC purchased a new position in shares of Insmed during the second quarter valued at approximately $137,000. Cubist Systematic Strategies LLC purchased a new position in shares of Insmed during the second quarter valued at approximately $278,000. State Board of Administration of Florida Retirement System raised its position in shares of Insmed by 1.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 29,335 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 278 shares during the period. Finally, RidgeWorth Capital Management LLC raised its position in shares of Insmed by 52.2% in the second quarter. RidgeWorth Capital Management LLC now owns 29,843 shares of the biopharmaceutical company’s stock valued at $301,000 after buying an additional 10,241 shares during the period. Hedge funds and other institutional investors own 90.53% of the company’s stock.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal.
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.